NeOnc Technologies, Inc. (NTI) is an early-stage cancer biotechnology company focused initially on intranasal (delivery through the nose) inhalation and other non traditional delivery of a novel, highly purified form of monoterpenes (oils from fruits & plants), alone or with other chemotherapeutic (cancer treatment chemicals) agents. It will initially be used in clinical research for second line or salvage treatment of malignant brain cancer (gliomas) and other aggressive brain cancer.
The Company has assembled a highly qualified Management Team. NTI is developing several proprietary molecules for clinical research some of which have demonstrated significant activity (positive results) in laboratory tests. NTI is accordingly building a portfolio of intellectual property around this research. In addition, the Company has reached an agreement with a manufacturer of active pharmaceutical ingredients for development and production of proprietary monoterpenes.
Promising Research
The results obtained in the on-going Brazilian study are very encouraging. NTI management has completed due diligence on this work in the overseas location and has signed agreements with the local research team to join the Company. NTI also has an exclusive license on a patent application filed by the University of Southern California in 2009 for the use of monoterpenes in cancer therapy, alone and in conjunction with other therapeutic agents. Based on the development work, NTI is developing a patent portfolio in order to protect the commercialization of this novel therapeutic technique. NTI has an active IND (investigative new drug application) for its proprietary form of perillyl alcohol and is currently preparing clinical trials at Cleveland Clinic and the University of Southern California Keck School of Medicine.
The research demonstrated that intranasal delivery permits bypass of the blood brain barrier, enabling NTI to address the US market for brain cancer treatment, in which total primary and secondary incidents totaled more than 180,000 in 2008. The drug was well tolerated and did not cause severe side effects that would negatively impact quality of life.
Differentiation
Intranasal monoterpene therapy has demonstrated several key benefits in treatment of brain gliomas and lung cancer. The efficacy of this treatment method has not been achieved previously. The Brazilian clinical results showed that the drug was well-tolerated. The therapy is non-invasive and therefore considerably improves patient quality of life.
The research overseas demonstrated that intranasal delivery permits bypass of the blood brain barrier, enabling NeOnc Technologies to address the US market for brain cancer treatment, in which total primary and secondary incidents are estimated to be more than 75,000 in 2016. The drug was well tolerated and did not cause severe side effects that would negatively impact quality of life.
Intranasal monoterpene therapy has demonstrated several key benefits in treatment of brain gliomas. The efficacy of this treatment method has not been achieved previously. The Brazilian clinical results showed that the drug was well-tolerated. The therapy is non-invasive and therefore considerably improves patient quality of life.